The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-04), BridgeBio Pharma's 9-Day RSI is 82.86.
The industry rank for BridgeBio Pharma's 9-Day RSI or its related term are showing as below:
FRA:2CL's 9-Day RSI is ranked worse than 97.12% of 1422
companies
in the Biotechnology industry
Industry Median: 51.47
vs FRA:2CL: 82.86
BridgeBio Pharma (FRA:2CL) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
BridgeBio Pharma 9-Day RSI Related Terms
FRA:2CL vs EXEL, IONS, JAZZ: 9-Day RSI Comparison
For the Biotechnology subindustry, BridgeBio Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a 9-Day RSI of 82.86 as of Jul. 04, 2026. According to the industry distribution chart, BridgeBio Pharma ranks #1381 out of 1422 companies in the Biotechnology industry, placing it in the top 97.1%.
Is BridgeBio Pharma's 9-Day RSI too high?
BridgeBio Pharma's current 9-Day RSI is 82.86. The Biotechnology industry median 9-Day RSI is 51.47. BridgeBio Pharma's value of 82.86 is 61% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #1381 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's 9-Day RSI compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #1381 out of 1422 companies for 9-Day RSI. This places BridgeBio Pharma in the lower half of its industry. The industry median 9-Day RSI is 51.47. BridgeBio Pharma's value of 82.86 is 61% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current 9-Day RSI of 82.86 is 61% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current 9-Day RSI is 82.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €127.74, compared to a current price of €67.60 — trading 47.1% below its estimated fair value. The current 9-Day RSI is 82.86 and 61% above the Biotechnology industry median of 51.47. BridgeBio Pharma's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current 9-Day RSI is 82.86 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €67.60 is trading 47.1% below its estimated GF Value™ of €127.74.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
9-Day RSI: 82.86
GF Value™: €127.74 vs. price of €67.60 (47.1% below fair value)
Industry Position: 61% above the Biotechnology median (#1381 of 1422)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
67GF Score
Get the complete analysis for FRA:2CL
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 